Genedx Holdings CORP Form 4 insider transactions

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the acquisition of shares from restricted stock unit vesting and a subsequent sale to cover tax withholding obligations.

Keith A. Meister, affiliated with Corvex Management LP, reports purchasing additional shares of GeneDx Holdings Corp., increasing the firm's holdings.

Keith Meister, affiliated with Corvex Management LP, reports purchasing additional shares of GeneDx Holdings Corp., increasing their beneficial ownership.

Kevin Feeley, CFO of GeneDx Holdings Corp., amended his Form 4 filing to correct a previously reported error in the amount of Class A Common Stock sold following a stock option exercise.

Keith A. Meister, through Corvex Management LP, has increased his indirect holdings in GeneDx Holdings Corp. (WGS) through a series of Class A Common Stock acquisitions.

Richard C. Pfenniger Jr., a director of GeneDx Holdings Corp., acquired 918 shares of Class A Common Stock on May 2, 2025, through the vesting of restricted stock units.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the vesting and sale of Class A Common Stock to cover tax obligations.

Kevin Feeley, CFO of GeneDx Holdings Corp., exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan on April 9, 2025.

GeneDx Holdings CEO Katherine Stueland sold shares of Class A Common Stock on April 9, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the vesting and sale of Class A Common Stock to cover tax obligations.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports transactions involving Class A Common Stock, including the vesting and sale of restricted stock units to cover tax withholding obligations.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports sales of Class A Common Stock to cover tax obligations and the vesting of Restricted Stock Units (RSUs), along with new RSU grants.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports stock sales to cover tax obligations and the grant and vesting of restricted stock units (RSUs).

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Director Joshua Ruch exercised stock options to acquire shares of GeneDx Holdings Corp. Class A Common Stock on February 5, 2025.

GeneDx Holdings CFO Kevin Feeley sold 275 shares of Class A Common Stock to cover tax obligations after the vesting of 753 Restricted Stock Units (RSUs).

GeneDx Holdings CEO, Katherine Stueland, sold 1,657 shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.

Director Joshua Ruch exercised stock options to acquire 3,000 shares of Class A Common Stock in GeneDx Holdings Corp.

Bryan Dechairo, Chief Operating Officer of GeneDx Holdings Corp., was granted 37,497 restricted stock units (RSUs) on January 14, 2025.

GeneDx Holdings Corp. CFO Kevin Feeley exercised stock options and sold a portion of his holdings in Class A Common Stock on January 7, 2025.

GeneDx Holdings Corp. CEO, Katherine Stueland, sold a total of 51,360 shares of Class A Common Stock on January 7, 2025, under a pre-arranged 10b5-1 trading plan.

Katherine Stueland, CEO of GeneDx Holdings Corp., sold shares of Class A Common Stock on January 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

GeneDx Holdings Corp. CFO Kevin Feeley sold a total of 1,430 shares of Class A Common Stock on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

GeneDx Holdings Corp. CEO Katherine Stueland sold 10,501 shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.

GeneDx Holdings CFO Kevin Feeley sold 3,728 shares of Class A Common Stock at $76.7541 per share to cover tax obligations following the vesting of restricted stock units.

GeneDx Holdings CEO, Katherine Stueland, sold 3,661 shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.

GeneDx Holdings CFO, Kevin Feeley, sold shares to cover tax obligations related to the vesting of restricted stock units.